血液学
医学
淋巴细胞白血病
肿瘤科
移植
造血干细胞移植
造血细胞
内科学
维持疗法
造血
急性白血病
费城染色体
白血病
干细胞
急性淋巴细胞白血病
免疫学
化疗
生物
染色体易位
遗传学
基因
作者
Jun Kong,Fengmei Zheng,Chen‐Hua Yan,Jingzhi Wang,Haixia Fu,Zhidong Wang,Pan Suo,Guan-Hua Hu,Meng Lv,Huan Chen,Xiao‐Dong Mo,Lan‐Ping Xu,Xiaohui Zhang,Xiaojun Huang,Yu Wang
标识
DOI:10.1007/s00277-025-06198-0
摘要
Abstract Experience using olverembatinib as maintenance therapy in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph + ALL) after allogeneic hematopoietic cell transplantation (allo-HCT) is limited. We retrospectively collected data from 26 patients with Ph + ALL who received only olverembatinib as maintenance therapy after allo-HCT. Olverembatinib was administered as prophylaxis in 18 patients (69.2%), and preemptively in 8 patients (30.8%). The median time of olverembatinib initiation after transplantation was 2.5 months (range, 1-7.3). The median starting dose of olverembatinib was 35 mg qod (range, 15–40). The median duration of olverembatinib treatment was 12.5 months (range, 6–23). Olverembatinib maintenance treatment was discontinued in 8 patients (8/26,30%), seven stopped the drug for a long-lasting BCR-ABL1 negativity and 1 for recurrent fever associated with the drug. BCR-ABL1 turned positive in 3 patients in 2, 3 and 6 months after discontinuation. During olverembatinib treatment, three patients developed grade ≥ 3 hematologic side effects, which resolved with dose interruption or dose reduction. The median follow-up time after allo-HCT were 17.75 months (range 7–31). The hematologic relapse rate was 7.7% (2/26), with no event in the preemptive group. The 3-year probability of overall survival and relapse free survival after allo-HCT was 91.7% and 79.1%, respectively. Only one patient in prophylaxis group died of central central nervous system (CNS) relapse. Thus, our data suggest that olverembatinib is effective and safe as maintenance treatment in patients with Ph + ALL who underwent allo-HSCT. The main adverse effect was hematologic toxicity, which was tolerated.
科研通智能强力驱动
Strongly Powered by AbleSci AI